Cervical Cancer is one of the most common cancers amongst women. It is the third most commonly diagnosed cancers and the fourth leading cause of cancer deaths in females worldwide.
According to the Whole Health Organization (WHO) – ‘Cervical cancer is by far the most common HPV-related disease. Nearly all cases of cervical cancer can be attributed to HPV infection. Although most HPV infections clear up on their own and most pre-cancerous lesions resolve spontaneously, there is a risk for all women that HPV infection may become chronic and pre-cancerous lesions progress to invasive cervical cancer.’
It has been shown that a single round of HPV screening can cause a significant reduction in the severity and mortality of the disease.
Combing the strengths of the LBC technology which delivers greater accuracy and Molecular assays for enhanced specificity, the LABASSURE Cervical Cancer Screening Program is your essential partner for early detection of cervical cancer.
Liquid Based Cytology (LBC) is an advanced liquid PAP test with enhanced accuracy through higher celluloid yield, greater sensitivity and easier sample handling. Our screening protocol involves a very simple sample collection mechanism with enhanced sample stability enabling longer transportation and reuse. Re-sampling for additional molecular testing can also be avoided as the DNA for molecular testing can be obtained from the same sample.
PCR based molecular technologies enable a direct evaluation of the cervical cancer mutations leading to far greater sensitivity and specificity than routine screening protocols. Our HPV DNA PCR test is designed to identify the PCR infection at a molecular level and confirm the diagnosis, differentiation and identification of the High Risk and Low Risk HPV genotypes.